{"issuance_frequency":"","notes_translated":{"fr":"Le but du présent avis est d'informer les promoteurs de présentations de drogue en vertu du Titre 8 du Règlement sur les aliments et drogues (c'est-à-dire [c.-à-d.] drogue nouvelle et présentation abrégée de drogue nouvelle) des modifications aux exigences en matière de biodisponibilité comparative de Santé Canada, pour les produits pharmaceutiques présentant d'importantes variations pharmacocinétiques chez un même sujet en ce qui a trait au degré d'absorption mesuré par la surface sous la courbe (SSC) de la concentration en fonction du temps.","en":"This Notice serves to inform sponsors of drug submissions pursuant to Division C.08 of the Food and Drug Regulations (that is [i.e.], new drug and abbreviated new drug submissions) of changes in Health Canada's comparative bioavailability requirements for drug products which exhibit large pharmacokinetic within-subject variation in extent of absorption, as measured by area under the concentration versus time curve (AUC)."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"b9d49823-99e5-470a-8ce8-4b44da49b045","metadata_created":"2021-06-01T17:11:53.245177","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-06-01T17:11:53.245183","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-06-01","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["document d'orientation","présentations de médicaments","présentations de médicaments nouveaux","politique sur les normes de bioéquivalence","produits pharmaceutiques très variables","exigences de biodisponibilité comparative","pharmacocinétique"],"en":["guidance document","drug submissions","new drug submissions","policy on bioequivalence standards","highly variable drug products","comparative bioavailability requirements","pharmacokinetic"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Avis : Politique sur les normes de bioéquivalence pour les produits pharmaceutiques à haute variabilité","en":"Notice: Policy on Bioequivalence Standards for Highly Variable Drug Products"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"b9d49823-99e5-470a-8ce8-4b44da49b045","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"626d6a89-5f48-4555-b920-b54bf1b7d65a","related_relationship":"","name_translated":{"fr":"Avis : Politique sur les normes de bioéquivalence pour les produits pharmaceutiques à haute variabilité","en":"Notice: Policy on Bioequivalence Standards for Highly Variable Drug Products"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Notice: Policy on Bioequivalence Standards for Highly Variable Drug Products","language":["en"],"created":"2021-06-01T17:11:53.315401","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/notice-policy-bioequivalence-standards-highly-variable-drug-products.html","last_modified":null,"position":0,"revision_id":"0e25a0f0-27ea-4f77-ad76-9e28fb639d46","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"b9d49823-99e5-470a-8ce8-4b44da49b045","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"9310a161-4507-4874-9a85-f62be5898e2a","related_relationship":"","name_translated":{"fr":"Avis : Politique sur les normes de bioéquivalence pour les produits pharmaceutiques à haute variabilité","en":"Notice: Policy on Bioequivalence Standards for Highly Variable Drug Products"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Notice: Policy on Bioequivalence Standards for Highly Variable Drug Products","language":["fr"],"created":"2021-06-01T17:11:53.315407","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/annonces/avis-politique-normes-bioequivalence-produits-pharmaceutiques-haute-variabilite.html","last_modified":null,"position":1,"revision_id":"0e25a0f0-27ea-4f77-ad76-9e28fb639d46","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2016-04-18 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"b9d49823-99e5-470a-8ce8-4b44da49b045","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"This Notice serves to inform sponsors of drug submissions pursuant to Division C.08 of the Food and Drug Regulations (that is [i.e.], new drug and abbreviated new drug submissions) of changes in Health Canada's comparative bioavailability requirements for drug products which exhibit large pharmacokinetic within-subject variation in extent of absorption, as measured by area under the concentration versus time curve (AUC).","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Notice: Policy on Bioequivalence Standards for Highly Variable Drug Products","revision_id":"0e25a0f0-27ea-4f77-ad76-9e28fb639d46"}